Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
10.1093/annonc/mdy550
Saved in:
Main Authors: | Sundar, R, Huang, KK, Qamra, A, Kim, K-M, Kim, ST, Kang, WK, Tan, ALK, Lee, J, Tan, P |
---|---|
Other Authors: | DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) |
Format: | Article |
Language: | English |
Published: |
OXFORD UNIV PRESS
2019
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/155022 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
by: Sundar, R., et al.
Published: (2021) -
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
by: Ngoi, NYL, et al.
Published: (2021) -
Microbial synthesis of Prussian blue for potentiating checkpoint blockade immunotherapy
by: Wang, Dongdong, et al.
Published: (2023) -
EPIGENOMIC PROMOTER PROFILING OF GASTRIC ADENOCARCINOMA
by: ADITI QAMRA
Published: (2017) -
IMMUNOTHERAPY AGAINST ADVANCED CANCERS – CHIMERIC ANTIGEN RECEPTOR-BASED APPROACH AND IMMUNE CHECKPOINT REGULATION
by: TAY CHIN KANG JOHAN
Published: (2019)